IDNA stock forecast, quote, news & analysis

The most notable companies in this group are Merck & Co (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.

The average market capitalization across the iShares Genomics Immnlgy & Hlthcr ETF ETF is 19.87B. The market cap for tickers in the group ranges from 180.2M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is CRBU at 180.2M.

The average weekly price growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was -9%. For the same ETF, the average monthly price growth was -7%, and the average quarterly price growth was -5%. FDMT experienced the highest price growth at 9%, while CRBU experienced the biggest fall at -26%.

The average weekly volume growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was 35%. For the same stocks of the ETF, the average monthly volume growth was 79% and the average quarterly volume growth was 105%